Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Endothelin-1 (8-21), Succinyl-(glu(9),ala(11,15))-
2. Irl 1620
3. Irl-1620
4. Spi-1620
5. Succinyl-(glu(9),ala(11,15))-endothelin-1 (8-21)
6. Succinyl-(glutamyl(9)-alanyl(11,15))-endothelin-1 (8-21)
1. Spi-1620
2. Deeavyfahldiiw
3. C86h117n17o27
4. Suc[glu9,ala11,15]et-110-21
5. (asp-1 = Suc-asp)
6. Spi 1620
7. Gtpl3886
8. Chembl3188091
9. Irl1620
10. Irl2620
11. Mfcd00214284
12. Akos024456459
13. Suc-asp-glu-glu-ala-val-tyr-phe-ala-his-leu-asp-ile-ile-trp-oh
14. Succinyl-(glu9,ala11 Inverted Exclamation Mark Currency15)-endothelin-1 (8-21)
15. Succinyl-(glu9,ala11?15)-endothelin-1 (8-21) (suc-asp-glu-glu-ala-val-tyr-phe-ala-his-leu-asp-ile-ile-trp)
Molecular Weight | 1820.9 g/mol |
---|---|
Molecular Formula | C86H117N17O27 |
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 23 |
Hydrogen Bond Acceptor Count | 28 |
Rotatable Bond Count | 56 |
Exact Mass | 1819.83048152 g/mol |
Monoisotopic Mass | 1819.83048152 g/mol |
Topological Polar Surface Area | 696 Ų |
Heavy Atom Count | 130 |
Formal Charge | 0 |
Complexity | 3920 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 16 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
Tycamzzi (Sovateltide), is a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, which is investigated for the treatment of acute cerebral ischemic stroke patients.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Brand Name: Tycamzzi
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Lead Product(s) : Sovateltide
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tycamzzi (Sovateltide), is a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, which is investigated for the treatment of acute cerebral ischemic stroke patients.
Brand Name : Tycamzzi
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 02, 2023
Details:
Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Brand Name: Tyvalzi
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2023
Lead Product(s) : Sovateltide
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmazz Inc. and Sun Pharma Enter into Licensing Agreement for Introducing Tyvalzi™ (sovateltid...
Details : Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.
Brand Name : Tyvalzi
Molecule Type : Peptide
Upfront Cash : Undisclosed
September 13, 2023
Details:
Tycamzzi, a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, receives marketing approval in India for the treatment of acute cerebral ischemic stroke. Sovateltide is in Phase 3 trial in US for the same indication.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Brand Name: Tycamzzi
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Lead Product(s) : Sovateltide
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tycamzzi, a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, receives marketing approval in India for the treatment of acute cerebral ischemic stroke. Sovateltide is in Phase 3 trial in US for the sa...
Brand Name : Tycamzzi
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 31, 2023
Details:
Tycamzzi (sovateltide) is a highly selective endothelin-B receptor agonist, having the potential to be a neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in acute cerebral ischemic stroke patients.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Brand Name: Tycamzzi
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Lead Product(s) : Sovateltide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tycamzzi (sovateltide) is a highly selective endothelin-B receptor agonist, having the potential to be a neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in acute cerebral ische...
Brand Name : Tycamzzi
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 13, 2023
Details:
Results of this trial shows highly encouraged regarding the potential of Tycamzzi (sovateltide) to be the first therapeutic since tPA to demonstrate a positive impact on patients suffering from acute ischemic stroke.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Brand Name: Tycamzzi
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Lead Product(s) : Sovateltide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results of this trial shows highly encouraged regarding the potential of Tycamzzi (sovateltide) to be the first therapeutic since tPA to demonstrate a positive impact on patients suffering from acute ischemic stroke.
Brand Name : Tycamzzi
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 10, 2023
Details:
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Brand Name: PMZ-1620
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Lead Product(s) : Sovateltide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s ...
Details : PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke pa...
Brand Name : PMZ-1620
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 31, 2022
Details:
Tycamzzi (sovateltide), an endothelin-B receptor agonist, has been previously shown to increase cerebral blood flow, have anti-apoptotic activity and produce neurovascular remodeling when administered IV following acute cerebral ischemic stroke in rats.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Brand Name: Tycamzzi
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Lead Product(s) : Sovateltide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tycamzzi (sovateltide), an endothelin-B receptor agonist, has been previously shown to increase cerebral blood flow, have anti-apoptotic activity and produce neurovascular remodeling when administered IV following acute cerebral ischemic stroke in rats.
Brand Name : Tycamzzi
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 26, 2022
Details:
PMZ-1620 (sovateltide) is endothelin-B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects neural mitochondria, and produces neurovascular remodeling. Sovateltide is undergoing MA review by CDSCO for acute cerebral ischemic stroke.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Brand Name: PMZ-1620
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Lead Product(s) : Sovateltide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PMZ-1620 (sovateltide) is endothelin-B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects neural mitochondria, and produces neurovascular remodeling. Sovateltide is undergoing MA review by CDSCO for acute cerebral ischemi...
Brand Name : PMZ-1620
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 29, 2022
Details:
PMZ-1620 having Sovateltide as API, is the Company’s endothelin-B receptor agonist that is also in a Phase III trial for the treatment of cerebral ischemic stroke. In clinical trials, subjects will receive either three intravenous doses of sovateltide, 0.3 ug/kg or a placebo.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Brand Name: PMZ-1620
Study Phase: IND EnablingProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2022
Lead Product(s) : Sovateltide
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PMZ-1620 having Sovateltide as API, is the Company’s endothelin-B receptor agonist that is also in a Phase III trial for the treatment of cerebral ischemic stroke. In clinical trials, subjects will receive either three intravenous doses of sovateltide,...
Brand Name : PMZ-1620
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 03, 2022
Details:
The interim analysis of data indicates a numerical difference indicative of a potential beneficial effect of sovateltide in Alzheimer's disease patients with late early to moderate stage disease.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Brand Name: PMZ-1620
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Lead Product(s) : Sovateltide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The interim analysis of data indicates a numerical difference indicative of a potential beneficial effect of sovateltide in Alzheimer's disease patients with late early to moderate stage disease.
Brand Name : PMZ-1620
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 10, 2021
21 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/21/2933391/0/en/Pharmazz-Inc-and-Sun-Pharma-entered-into-an-agreement-under-which-Sun-Pharma-will-invest-up-to-15-Million-in-Pharmazz-Inc.html
02 Oct 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/10/02/2752648/0/en/A-Special-Protocol-Assessment-Agreement-Reached-with-the-U-S-Food-and-Drug-Administration-for-Phase-3-clinical-trial-of-Sovateltide-for-the-treatment-of-acute-cerebral-ischemic-str.html
13 Feb 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/pharmazz-inc-announces-us-fda-clearance-for-a-phase-iii-clinical-trial-of-sovateltide-pmz-1620-in-acute-cerebral-ischemic-stroke-patients-301744465.html
10 Feb 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/clinical-phase-iii-trial-results-demonstrating-sovateltides-efficacy-to-treat-acute-cerebral-ischemic-stroke-presented-at-the-international-stroke-conference-2023-301741886.html
31 Oct 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/10/31/2544513/0/en/Pharmazz-Inc-Presents-Positive-Results-of-Phase-III-Clinical-Trial-Demonstrating-Sovateltide-s-Efficacy-as-a-Treatment-for-Acute-Cerebral-Ischemic-Stroke.html
29 Aug 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/08/29/2505915/0/en/Pharmazz-Inc-announces-Indian-Central-Drugs-Standard-Control-Organization-CDSCO-Clearance-of-IND-to-conduct-a-Phase-II-clinical-trial-of-sovateltide-PMZ-1620-in-hypoxic-ischemic-en.html
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?